CYT 0851 companion diagnostic - Cyteir Therapeutics
Alternative Names: CYT-0851 companion diagnostic assayLatest Information Update: 10 May 2024
At a glance
- Originator Cyteir Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 10 May 2024 Discontinued - Preclinical for Haematological malignancies (Diagnosis) in USA (unspecified route) prior to May 2024 (Cyteir Therapeutic pipeline, May 2024)
- 10 May 2024 Discontinued - Preclinical for Solid tumours (Diagnosis) in USA (unspecified route) prior to May 2024 (Cyteir Therapeutic pipeline, May 2024)
- 20 Mar 2024 Cyteir Therapeutics winds down its business and remains no longer active (Cyteir Therapeutic pipeline, May 2024)